Sunil Abhyankar is an Oncology physician affiliated with Health Innovations. OpenAlex indexes 341 publications with 4,646 citations (h-index 30); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
2330 Shawnee Mission Pkwy
Ms 5003
Westwood, KS 662052005
Telephone
913-588-6030Registry record last updated 6 May 2013.
Clinical trials
- Pilot Study: Patients With Chronic Active Graft Versus Host Disease That Have Failed or Not Tolerated Standard Therapy.
Sponsor: University of Kansas Medical Center
- A Safety Study Looking at the Combination of Velcade and G-CSF in Patients With Myeloma or Lymphoma
Sponsor: University of Kansas Medical Center
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
8 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Incyte CorporationProgram year20257 payments
- CSL BehringProgram year20252 payments
- Genmab U.S., Inc.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
32.3%Short-acting sulfonamides16.2%Sulfamethoxazole-Trimethoprim100%Part D≥31 patientsAzole Antifungal5.9%Posaconazole53%Fluconazole47%Part D<11 patients+ 3 more classes in this area
Metabolism & gastrointestinal
18.8%Proton pump inhibitor5.9%Pantoprazole Sodium58%Omeprazole42%Part D<11 patientsCorticosteroid5.2%Prednisone100%Part D<11 patients+ 3 more classes in this area
Dermatology
18.1%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor18.1%Acyclovir100%Part D≥37 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- “Waitlist mortality” is high for myeloma patients with limited access to BCMA therapy
Frontiers in Oncology
2023 - Impact of COVID‐19 in hematopoietic stem cell transplant recipients: A systematic review and meta‐analysis
Transplant Infectious Disease
2022 - Age is no barrier for adults undergoing HCT for AML in CR1: contemporary CIBMTR analysis
Bone Marrow Transplantation
2022
Similar KOLs
Other experts from the same institution or the same specialty.
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”